Core Viewpoint - Perrigo Company plc is optimizing its growth model focused on global Category Leadership and Market Activation to enhance agility, innovation, and sustainable growth, aligning with its 'Three-S' plan [1][2]. Organizational Changes - Roberto Khoury has been appointed as EVP and Chief Commercial Officer to lead global market activation, while the roles of EVP and President CSCI and EVP and President CSCA will be discontinued, with Triona Schmelter leaving the organization [1][4][6]. Growth Model Highlights - The new alignment aims to enhance speed, agility, and scalability, reducing bureaucracy and allowing Perrigo to serve a broader consumer base across various price points [6]. - The growth model has already shown success in the CSCI business and is increasingly effective in the CSCA business, achieving accelerated regulatory milestones and market share gains [6]. Portfolio Optimization - The alignment is designed to unlock value from both brand and store brand portfolios, creating new growth opportunities through enhanced global brand-building capabilities [6]. - Market-empowered activation and strong customer relationships will drive execution excellence in the new model [6]. Leadership Alignment - Roberto Khoury will oversee operating results in both CSCI and CSCA, collaborating closely with David Ball, who is responsible for global category leadership [6]. Financial Guidance - The organizational changes will not affect the full-year 2025 adjusted EPS guidance or reporting segments [6].

Core Insights - Perrigo Company plc announced the retirement of Ron Janish, EVP Global Operations and Supply Chain, effective September 30, 2025, after over two decades with the company [1][2] - Matt Winterman has been appointed as the new EVP Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025, bringing over 20 years of experience in global supply chain and strategy [1][3] Group 1: Leadership Transition - Ron Janish played a crucial role in aligning Perrigo's supply chain with its transformation into a consumer self-care leader and led the Supply Chain Reinvention program, which improved forecast accuracy and reduced portfolio complexity [2] - Matt Winterman previously served as SVP of Global Supply Chain and Strategy at AstraZeneca, overseeing a $54 billion supply chain, and has held significant roles at Roche and GSK [3] Group 2: Strategic Importance - The leadership transition is expected to enhance Perrigo's manufacturing and supply chain capabilities, supporting the execution of its long-term consumer self-care strategy [4] - Winterman expressed his commitment to driving initiatives that ensure the supply chain operates at high standards, delivering self-care solutions reliably to consumers [4] Group 3: Company Overview - Perrigo is a leading self-care company with over a century of experience, primarily serving consumers in North America and Europe [5] - The company offers a range of over-the-counter self-care solutions, ensuring accessibility and choice across various product categories [5][6]

Company Overview - Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions primarily in North America and Europe [2] - The company is a pioneer in the over-the-counter (OTC) self-care market, offering trusted self-care solutions that do not require a prescription, ensuring accessibility and choice for consumers across various molecules, dosage forms, and value tiers [2] Business Model - Perrigo's unique business model leverages complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®, and Solpadeine® [3] Upcoming Events - President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference on June 10 at 9 AM ET, which will be conducted virtually [1]

Core Insights - The company advanced its 'Three-S' Plan to stabilize, streamline, and strengthen its operations, achieving strong first-quarter results driven by infant formula and OTC brands [1][4] - The fiscal year 2025 outlook for reported net sales growth has been widened to 0% to 3% from 1% to 3%, while reaffirming other financial targets including adjusted EPS [2][38] - The company is facing macroeconomic uncertainties, including tariffs, which are expected to impact costs, but it remains confident in its financial targets due to proactive measures [4][34] Financial Performance - First-quarter 2025 net sales were $1.04 billion, a decline of 3.5% year-over-year, primarily due to divested businesses and currency translation [8][11] - Adjusted diluted EPS increased by 106.9% to $0.60, driven by higher adjusted operating income and lower interest expenses [17][10] - Reported gross margin improved to 37.6%, up 450 basis points from the prior year, while adjusted gross margin expanded to 41.0% [14][10] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 3.6% to $621 million, impacted by lost distribution of lower-margin products and lack of prior year benefits from new product launches [19][21] - Consumer Self-Care International (CSCI) net sales declined by 3.4% to $423 million, although organic net sales grew by 4.5% due to strong performance in specific categories [26][27] Strategic Initiatives - Project Energize aims to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026, with $40 million to $60 million expected to be reinvested [7][6] - The company has achieved gross annual savings of approximately $159 million since the program's inception, with restructuring charges of $111 million incurred [7][6] Cash Flow and Balance Sheet - First-quarter 2025 cash from operations was a loss of $65 million, primarily due to inventory rebuilding and restructuring costs [32] - As of March 29, 2025, cash and cash equivalents were $410 million, with total debt at $3.63 billion [33][50]